Successful biotech companies developing treatments for Rare Disease build specialized and holistic global strategies and further adapting their approaches to the local market environments. Specifically in Europe, no unified framework exists for evaluating the benefit of such treatments for Rare Diseases. Local expertise is essential to monitor on regular basis the constant changes of evaluation processes for Rare Disease Treatments and address concerns and risk of local payers accordingly.